 After measurement of hepatic venous pressure gradient and liver stiffness at baseline a non-selective beta-blocker NSBB,carvedilol was initiated and increased stepwise weekly until the systolic blood pressure remained at100 mmHg and the heart rate was not 60. The maximum target dose for carvedilol 25 mgday. The hepatic venous pressure gradient response to NSBB was again assessed 6 weeks after the intake of carvedilol. A hemodynamic response to NSBB treatment was defined as a reduction in hepatic venous pressure gradient 20 compared to baseline or to an absolute value 12 mmHg. Compliance with therapy was monitored by monitoring of heart rate and blood pressure during clinical visits. 